Four months after a safety signal blew Theseus Pharmaceuticals’ quest to develop a gastrointestinal stromal tumor (GIST) treatment off course, the biotech is shrinking its head count by almost three-quarters.

四个月前，一个安全信号使特修斯制药公司（Theseus Pharmaceuticals）寻求开发胃肠道间质瘤（GIST）治疗方法的努力偏离了轨道，四个月后，这家生物技术公司的员工人数减少了近四分之三。

The hefty layoffs form part of a “process exploring strategic alternatives,” Theseus announced in a sparse postmarket release Nov 13. “As part of this process, the company plans to consider a wide range of options with a focus on maximizing shareholder value, including potential sale of assets of the company, a sale of the company, a merger or other strategic action,” it explained..

特修斯（Theseus）在11月13日发布的一份稀疏的上市后公告中宣布，大规模裁员是“探索战略替代方案的过程”的一部分。它解释道：“作为这一过程的一部分，公司计划考虑多种选择，重点是股东价值最大化，包括潜在的公司资产出售、公司出售、合并或其他战略行动。”。。

Among the 72% of employees heading out of the door will be the company’s head of R&D, William Shakespeare, Ph.D., although he will continue to support the biotech in a consulting role until the end of June 2024.

在72%即将离职的员工中，将有公司研发负责人威廉·莎士比亚博士（WilliamShakespeare，Ph.D.），尽管他将在2024年6月底之前继续以咨询的身份支持生物技术。

Theseus still has some money to play with as the company ended September with $225.4 million in cash and equivalents.

特修斯（Theseus）仍有一些资金可供使用，截至9月，该公司拥有2.254亿美元现金及等价物。

Fortune turned against Theseus in July when the biotech reported dose-limiting toxicity from the trial of its GIST treatment that drove the company to stop enrollment and end development, sending its stock down 65%.

7月，《财富》杂志（Fortune）转而反对特修斯（Theseus），当时该生物技术公司（biotech）报告了其GIST治疗试验产生的剂量限制性毒性，导致该公司停止注册并终止开发，导致其股价下跌65%。

Today’s release didn’t provide an update on the remainder of the Massachusetts-based company’s pipeline, but Theseus had continued to sound upbeat about its prospects in an earnings update in August.

今天的发布并没有提供这家总部位于马萨诸塞州的公司剩余渠道的最新信息，但特修斯在8月份的盈利更新中继续对其前景表示乐观。

At the time, CEO Tim Clackson, Ph.D., said the biotech was “excited to be advancing our pipeline,” which is now headed up by an EGFR inhibitor called THE-349. The company expected to submit a request to the FDA in the fourth quarter for a trial of the therapy in EGFR-mutant non-small cell lung cancer, Clackson said..

当时，首席执行官蒂姆·克拉克森（TimClackson）博士表示，该生物技术公司“对推进我们的管道感到兴奋”，该管道目前由一种名为-349的EGFR抑制剂领导。克拉克森说，该公司预计将在第四季度向FDA提交一份申请，要求对EGFR突变型非小细胞肺癌进行治疗试验。。

The biotech hadn’t given up hope on that failed GIST treatment, either, Clackson said in that update. “Theseus is evaluating next steps for potential plans to explore doses of 9 mg and below in clinical studies in patients with mast cell-driven diseases, such as chronic urticaria,” he added at the time..

克拉克森在更新中说，生物技术也没有放弃对GIST治疗失败的希望。他当时补充道：“特修斯正在评估下一步的潜在计划，即在肥大细胞驱动的疾病（如慢性荨麻疹）患者的临床研究中探索9毫克及以下的剂量。”。。